Current Status of Clinical Drug Use in Patients with Hypertension and Hyperuricemia/Gout in 146 Hospitals in China
Objective To analyze the current status of combined use of anti-hypertensive drugs and uric acid-lowering drugs in patients with hypertension and hyperuricemia/gout in 146 hospitals in nine cities in China,and to provide a relevant reference for rational drug use in the clinic.Methods The outpatient prescription data of patients with hypertension and hyperuricemia/gout in 146 hospitals from January 2016 to December 2022(28 quarters)were extracted,and the clinical application of their medications was statistically analyzed and compared with those of patients with hypertension or hyperuricemia/gout.Results Amlodipine,nifedipine,and losartan were the three most commonly used anti-hypertensive drugs.The prescribing of febuxostat,has been increasing yearly from 2016 to 2022,and it has become the uric acid-lowering drug with the highest prescribing proportion from 2021 to 2022.Preferences for the types of drugs used in combination varied by department and region.Conclusion The commonly used combination regimen is febuxostat combined with amlodipine,nifedipine,or losartan for patients with hypertension and hyperuricemia/gout in 146 hospitals in China.However,there are still some prescriptions combining with anti-hypertensive medications such as β-receptor blockers,which can cause elevated levels of blood uric acid.
万方数据
维普
